Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06589063

Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis

LOW-TAVR is a real-world, retrospective and prospective, multicenter Italian registry aimed at evaluating the characteristics and clinical outcomes of patients with severe low flow, low gradient aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) and, in particular:

* risk factors * gender differences * comorbidities * pharmacological treatment * TAVR procedural characteristics * periprocedural and in-hospital complications * clinical outcome at 30-day, 1-year, 2-year and 5-year follow-up

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Salerno

Salerno, 84131, Italy

Location status: Recruiting

Location contact

Gennaro Galasso, MD, PhD

CONTACT

[email protected]

+393497441225

About this study

LOW-TAVR is a real-world, retrospective and prospective, multicenter Italian registry aimed at evaluating the characteristics and clinical outcomes of patients with severe low flow, low gradient aortic stenosis (LFLG-AS) undergoing transcatheter aortic valve replacement (TAVR).

The register aims to include at least 1350 patients diagnosed with LFLG-AS undergoing TAVR at the participating centres.

The inclusion criteria are:

  • LFLG-AS diagnosis according to current European Society of Cardiology guidelines
  • Age 18 years or older
  • Written informed consent

The exclusion criteria are:

  • LFLG-AS pseudo-severe or non-confirmed severe aortic stenosis
  • LFLG-AS referred for medical treatment or undergoing surgery

Clinical outcome is evaluated at a 30-day, 1-year, 2-year, and 5-year follow-up.

The primary endpoint of interest of the registry is the assessment of the incidence of the composite of all-cause mortality and hospitalization for heart failure at one year.

The secondary endpoints are the assessment of:

  • periprocedural TAVR complications: complete atrioventricular block, stroke, acute myocardial infarction, acute aortic insufficiency, cardiogenic shock, acute pulmonary edema, cardiac tamponade, aortic rupture;
  • adverse events during hospitalization: major and minor bleeding, major and minor vascular complications, definitive pacemaker implantation, cardiogenic shock, myocardial infarction, stroke, and death;
  • adverse events at 30 days, one year, two years, and five years: all-cause mortality, hospitalizations for heart failure, cardiovascular mortality, myocardial infarction, stroke, major and minor bleedings.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • LFLG-AS diagnosis according to current European Society of Cardiology guidelines
  • Age 18 years or older
  • Written informed consent

Exclusion criteria

  • LFLG-AS pseudo-severe or non-confirmed severe aortic stenosis
  • LFLG-AS referred for medical treatment or undergoing surgery

Treatment and study plan

Transcatheter Aortic Valve Replacement

Device

Transcatheter aortic valve replacement with implantation of new-generation balloon-expandable or self-expandable bioprostheses

Other names: TAVI, TAVR, Transcatheter aortic valve implantation

Primary outcomes

  1. Composite of all-cause death and hospitalization for worsening heart failure

    Time frame: 1 year

    Death due to cardiac or non-cardiac cause and new hospitalization for worsening heart failure

Study contacts

Contact information is provided by the study sponsor or research team.

Angelo Silverio, MD, PhD

CONTACT

[email protected]

3286924815

Gennaro Galasso, MD, PhD

CONTACT

[email protected]

3497441225

Sponsors and collaborators

Lead sponsor

University of Salerno

Other

Registry information

Official study title

Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis: the Multicenter LOW-TAVR Registry

Acronym: LOW-TAVR

Important dates

Study start
2024
Primary completion
2025
Study completion
2037
First posted
Sep 19, 2024
Registry last updated
Apr 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.